Upcoming Data Determines Direction
$NASDAQ:ADXS could have an interesting week ahead of it right now. Not only is it back at a clear level of support/resistance, the company has data to digest:
Despite the last few months of selling pressure, the last few weeks showed a bit more bullish momentum. In fact, ADXS stock jumped to highs of $0.7597 after releasing updated data from the ADXS-503 combination study with KEYTRUDA®. Ken Berlin, Chief Executive Officer of Advaxis, explained, “The clinical activity observed to date in this challenging patient population, combined with a favorable safety profile, suggest that ADXS-503 may be an important new off-the-shelf immunotherapy treatment option. We look forward to continued progress in the clinic with our ADXS-HOT products, which includes the ongoing Phase 1/2 study of ADXS-503 in NSCLC, and the expansion of the program to our planned Phase 1 Study of ADXS-504 for the treatment of early prostate cancer.” More details will be presented as a poster at the ASCO 2021 Annual Meeting this week.
Quote Source: Hot Penny Stocks To Buy On Robinhood With Upcoming Events This Week
Despite the last few months of selling pressure, the last few weeks showed a bit more bullish momentum. In fact, ADXS stock jumped to highs of $0.7597 after releasing updated data from the ADXS-503 combination study with KEYTRUDA®. Ken Berlin, Chief Executive Officer of Advaxis, explained, “The clinical activity observed to date in this challenging patient population, combined with a favorable safety profile, suggest that ADXS-503 may be an important new off-the-shelf immunotherapy treatment option. We look forward to continued progress in the clinic with our ADXS-HOT products, which includes the ongoing Phase 1/2 study of ADXS-503 in NSCLC, and the expansion of the program to our planned Phase 1 Study of ADXS-504 for the treatment of early prostate cancer.” More details will be presented as a poster at the ASCO 2021 Annual Meeting this week.
Quote Source: Hot Penny Stocks To Buy On Robinhood With Upcoming Events This Week
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.